SUBSCRIBE
SUBSCRIBE

Incyte

NEWS
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Deals
Why These 3 Drugmakers Could Buy Incyte
April 12, 2017
 · 
3 min read
Gilead Suffers Another R&D Setback as Myelofibrosis Drug Flops in Phase III, Gives Credence to Acquisition Urgency
Deals
What Happens if Gilead Went Bigger Than Incyte and Made a Play for This Pharma Giant
April 10, 2017
 · 
2 min read
BioCapital
After Soaring to $150, Can Incyte Stir Up More Upside?
March 16, 2017
 · 
1 min read
Deals
3 Reasons Why Gilead Will Buy Incyte—and 1 Reason Why It Won’t
March 15, 2017
 · 
1 min read
Bay Area Startup Arcus Biosciences Lands $307 Million+ Deal With Taiho Pharma
Deals
What a Gilead-Incyte Marriage Would Look Like
March 14, 2017
 · 
2 min read
Gilead Suffers Another R&D Setback as Myelofibrosis Drug Flops in Phase III, Gives Credence to Acquisition Urgency
Deals
Rumors Surface M&A-Desperate Gilead is Nearing a Deal to Buy Incyte
March 13, 2017
 · 
3 min read
Tiny KalVista Explodes on $760 Million Deal With Drug Giant Merck & Co.
Business
Bay Area’s Calithera Biosciences Rockets After Getting $53 Million Upfront in Cancer Deal With Incyte
January 30, 2017
 · 
2 min read
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Deals
Incyte Who? Why This Biotech Would Give Gilead a Bang for Its Buck
January 26, 2017
 · 
2 min read
3 Biotechs That Could be Taken Out This Quarter
Deals
Taking a Shot on Who Might Buy Incyte in 2017
December 27, 2016
 · 
2 min read
Load More
AWARDS
  • 2025 BPTW Badge - RBG.png
JOBS
IN THE PRESS
Press Releases
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
June 26, 2026
 · 
11 min read
Press Releases
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
June 19, 2026
 · 
9 min read
Press Releases
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
June 15, 2026
 · 
11 min read
Press Releases
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
June 15, 2026
 · 
14 min read
Press Releases
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
June 15, 2026
 · 
12 min read
Press Releases
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
June 8, 2026
 · 
8 min read
Press Releases
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
June 4, 2026
 · 
8 min read
Press Releases
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
June 1, 2026
 · 
13 min read
Press Releases
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
May 26, 2026
 · 
1 min read
Press Releases
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
May 20, 2026
 · 
5 min read
Load More